Download PDF
Am J Perinatol 2017; 34(01): 51-61
DOI: 10.1055/s-0036-1584147
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis

Evan J. Anderson
1   Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, Georgia
,
Leonard R. Krilov
2   Department of Pediatrics, Winthrop University Hospital, Mineola, New York
,
John P. DeVincenzo
3   Department of Pediatrics, CFRI at Le Bonheur Children's Hospital, University of Tennessee Center for Health Sciences, Memphis, Tennessee
,
Paul A. Checchia
4   Department of Pediatrics, Texas Children's Hospital, Houston, Texas
,
Natasha Halasa
5   Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
,
Eric A. F. Simões
6   Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado
,
Joseph B. Domachowske
7   Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York
,
Michael L. Forbes
8   Department of Pediatrics, Akron Children's Hospital, Akron, Ohio
,
Pia S. Pannaraj
9   Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California
,
Scott J. McBride
10   Department of Statistics, United BioSource Corporation, Ann Arbor, Michigan
,
Kimmie K. McLaurin
11   Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland
,
Veena R. Kumar
11   Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland
,
Christopher S. Ambrose
11   Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland
› Author Affiliations
Further Information

Publication History

04 February 2016

21 March 2016

Publication Date:
27 May 2016 (online)

Also available at
   Permissions and Reprints

Abstract

Objective SENTINEL1 characterized U.S. preterm infants 29 to 35 weeks' gestational age (wGA) < 12 months old hospitalized for laboratory-confirmed respiratory syncytial virus (RSV) disease and not receiving RSV immunoprophylaxis during the 2014 to 2015 RSV season.

Study Design This is a noninterventional, observational, cohort study.

Results A total of 702 infants were hospitalized with community-acquired RSV disease, of whom an estimated 42% were admitted to the intensive care unit (ICU) and 20% required invasive mechanical ventilation (IMV). Earlier gestational age and younger chronologic age were associated with an increased frequency of RSV-confirmed hospitalization (RSVH), ICU admission, and IMV. Among infants 29 to 32 wGA and < 3 months of age, 68% required ICU admission and 44% required IMV. One death occurred of an infant 29 wGA. Among the 212 infants enrolled for in-depth analysis of health care resource utilization, mean and median RSVH charges were $55,551 and $27,461, respectively, which varied by intensity of care required. Outpatient visits were common, with 63% and 62% of infants requiring visits before and within 1 month following the RSVH, respectively.

Conclusion Preterm infants 29 to 35 wGA are at high risk for severe RSV disease, which imposes a substantial health burden, particularly in the first months of life.

Keywords

preterm - infant - RSV - hospitalization - immunoprophylaxis - bronchiolitis - palivizumab - hospital charges

Supplementary Material

 

  • References

  • 1 Simões EA. Respiratory syncytial virus infection. Lancet 1999; 354 (9181) 847-852
    CrossrefPubMedSearch in Google Scholar
  • 2 Hall CB, Hall W. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995
    Search in Google Scholar
  • 3 Jain S, Williams DJ, Arnold SR , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372 (9) 835-845
    CrossrefPubMedSearch in Google Scholar
  • 4 Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137 (6) 865-870
    CrossrefPubMedSearch in Google Scholar
  • 5 Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011; 30 (6) 510-517
    CrossrefPubMedSearch in Google Scholar
  • 6 Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154 (1) 55-61
    PubMedSearch in Google Scholar
  • 7 DeVincenzo JP, McClure MW, Symons JA , et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015; 373 (21) 2048-2058
    CrossrefPubMedSearch in Google Scholar
  • 8 DeVincenzo JP, Whitley RJ, Mackman RL , et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371 (8) 711-722
    CrossrefPubMedSearch in Google Scholar
  • 9 Simões EA, DeVincenzo JP, Boeckh M , et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015; 211 (Suppl. 01) S1-S20
    CrossrefPubMedSearch in Google Scholar
  • 10 Blanken MO, Rovers MM, Molenaar JM , et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368 (19) 1791-1799
    CrossrefPubMedSearch in Google Scholar
  • 11 Feltes TF, Cabalka AK, Meissner HC , et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143 (4) 532-540
    CrossrefPubMedSearch in Google Scholar
  • 12 IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3) 531-537
    CrossrefPubMedSearch in Google Scholar
  • 13 American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012: 609-617
    Search in Google Scholar
  • 14 American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134 (2) 415-420
    CrossrefPubMedSearch in Google Scholar
  • 15 American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102 (5) 1211-1216
    CrossrefPubMedSearch in Google Scholar
  • 16 American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112 (6 Pt 1) 1442-1446
    CrossrefPubMedSearch in Google Scholar
  • 17 American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118 (4) 1774-1793
    CrossrefPubMedSearch in Google Scholar
  • 18 American Academy of Pediatrics Committee on Infectious Diseases. Policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124 (6) 1694-1701
    CrossrefPubMedSearch in Google Scholar
  • 19 Ambrose CS, Anderson EJ, Simões EA , et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J 2014; 33 (6) 576-582
    CrossrefPubMedSearch in Google Scholar
  • 20 Helfrich AM, Nylund CM, Eberly MD, Eide MB, Stagliano DR. Healthy late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev 2015; 91 (9) 541-546
    CrossrefPubMedSearch in Google Scholar
  • 21 Winterstein AG, Knox CA, Kubilis P, Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr 2013; 167 (12) 1118-1124
    CrossrefPubMedSearch in Google Scholar
  • 22 Centers for Disease Control and Prevention. Natality public-use data 2007–2014, on CDC WONDER Online Database. Available at: http://wonder.cdc.gov/natality-current.html . Accessed January 15, 2016
    PubMed
  • 23 Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999; 104 (4 Pt 1): 894-899
    CrossrefPubMedSearch in Google Scholar
  • 24 Carbonell-Estrany X, Quero J ; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001; 20 (9) 874-879
    CrossrefPubMedSearch in Google Scholar
  • 25 Cilla G, Sarasua A, Montes M , et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 2006; 134 (3) 506-513
    CrossrefPubMedSearch in Google Scholar
  • 26 Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J , et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008; 27 (9) 788-793
    CrossrefPubMedSearch in Google Scholar
  • 27 Greenbaum AH, Chen J, Reed C , et al. Hospitalizations for severe lower respiratory tract infections. Pediatrics 2014; 134 (3) 546-554
    CrossrefPubMedSearch in Google Scholar
  • 28 Lanari M, Giovannini M, Giuffré L , et al; Investigators R.A.D.A.R. Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol 2002; 33 (6) 458-465
    CrossrefPubMedSearch in Google Scholar
  • 29 Law BJ, Langley JM, Allen U , et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23 (9) 806-814
    CrossrefPubMedSearch in Google Scholar